 | • レポートコード：MRC23Q36427 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の腫瘍免疫治療市場について調査・分析し、世界の腫瘍免疫治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（免疫チェックポイント阻害剤、サイトカイン免疫療法、がんワクチン、Car-t細胞療法、その他）、用途別セグメント分析（病院、クリニック）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Bristol-Myers Squibb、Merck & Co., Inc.、Roche AG、AstraZeneca, Plc、Sanofi S.A.、Dendreon Pharmaceuticals、Novartis、Gilead Sciences Inc.、IMVAQ Therapeutics、Arch Oncology、Juno Therapeutics、Refuge、Lepu Biopharma、Genoimmune、TCR Cureなどが含まれています。世界の腫瘍免疫治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、腫瘍免疫治療市場規模を推定する際に考慮しました。本レポートは、腫瘍免疫治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、腫瘍免疫治療に関するビジネス上の意思決定に役立てることを目的としています。 ・腫瘍免疫治療市場の概要 - 腫瘍免疫治療のタイプ別セグメント - 世界の腫瘍免疫治療市場規模：タイプ別分析（免疫チェックポイント阻害剤、サイトカイン免疫療法、がんワクチン、Car-t細胞療法、その他） - 腫瘍免疫治療の用途別セグメント - 世界の腫瘍免疫治療市場規模：用途別分析（病院、クリニック） - 世界の腫瘍免疫治療市場規模予測（2018年-2029年） ・腫瘍免疫治療市場の成長トレンド - 腫瘍免疫治療の地域別市場規模（2018年-2029年） - 腫瘍免疫治療市場ダイナミクス - 腫瘍免疫治療の業界動向 - 腫瘍免疫治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：免疫チェックポイント阻害剤、サイトカイン免疫療法、がんワクチン、Car-t細胞療法、その他 - 世界の腫瘍免疫治療のタイプ別市場規模（2018年-2023年） - 世界の腫瘍免疫治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、クリニック - 世界の腫瘍免疫治療の用途別市場規模（2018年-2023年） - 世界の腫瘍免疫治療の用途別市場規模（2024年-2029年） ・腫瘍免疫治療の地域別市場規模 - 北米の腫瘍免疫治療市場規模（2018年-2029年） - アメリカの腫瘍免疫治療市場規模（2018年-2029年） - ヨーロッパの腫瘍免疫治療市場規模（2018年-2029年） - アジア太平洋の腫瘍免疫治療市場規模（2018年-2029年） - 中国の腫瘍免疫治療市場規模（2018年-2029年） - 日本の腫瘍免疫治療市場規模（2018年-2029年） - 韓国の腫瘍免疫治療市場規模（2018年-2029年） - インドの腫瘍免疫治療市場規模（2018年-2029年） - オーストラリアの腫瘍免疫治療市場規模（2018年-2029年） - 中南米の腫瘍免疫治療市場規模（2018年-2029年） - 中東・アフリカの腫瘍免疫治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Bristol-Myers Squibb、Merck & Co., Inc.、Roche AG、AstraZeneca, Plc、Sanofi S.A.、Dendreon Pharmaceuticals、Novartis、Gilead Sciences Inc.、IMVAQ Therapeutics、Arch Oncology、Juno Therapeutics、Refuge、Lepu Biopharma、Genoimmune、TCR Cure ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Tumor Immunity Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Tumor Immunity Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Tumor Immunity Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Tumor Immunity Therapy in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Tumor Immunity Therapy include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc. and IMVAQ Therapeutics, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Tumor Immunity Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Immunity Therapy.
The Tumor Immunity Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Tumor Immunity Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumor Immunity Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
IMVAQ Therapeutics
Arch Oncology
Juno Therapeutics
Refuge
Lepu Biopharma
Genoimmune
TCR Cure
Segment by Type
Immune Checkpoint Inhibitor
Cytokine Immunotherapy
Cancer Vaccine
Car-t Cell Therapy
Others
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tumor Immunity Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Immunity Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Immune Checkpoint Inhibitor
1.2.3 Cytokine Immunotherapy
1.2.4 Cancer Vaccine
1.2.5 Car-t Cell Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Tumor Immunity Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor Immunity Therapy Market Perspective (2018-2029)
2.2 Tumor Immunity Therapy Growth Trends by Region
2.2.1 Global Tumor Immunity Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Tumor Immunity Therapy Historic Market Size by Region (2018-2023)
2.2.3 Tumor Immunity Therapy Forecasted Market Size by Region (2024-2029)
2.3 Tumor Immunity Therapy Market Dynamics
2.3.1 Tumor Immunity Therapy Industry Trends
2.3.2 Tumor Immunity Therapy Market Drivers
2.3.3 Tumor Immunity Therapy Market Challenges
2.3.4 Tumor Immunity Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor Immunity Therapy Players by Revenue
3.1.1 Global Top Tumor Immunity Therapy Players by Revenue (2018-2023)
3.1.2 Global Tumor Immunity Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Tumor Immunity Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tumor Immunity Therapy Revenue
3.4 Global Tumor Immunity Therapy Market Concentration Ratio
3.4.1 Global Tumor Immunity Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Immunity Therapy Revenue in 2022
3.5 Tumor Immunity Therapy Key Players Head office and Area Served
3.6 Key Players Tumor Immunity Therapy Product Solution and Service
3.7 Date of Enter into Tumor Immunity Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor Immunity Therapy Breakdown Data by Type
4.1 Global Tumor Immunity Therapy Historic Market Size by Type (2018-2023)
4.2 Global Tumor Immunity Therapy Forecasted Market Size by Type (2024-2029)
5 Tumor Immunity Therapy Breakdown Data by Application
5.1 Global Tumor Immunity Therapy Historic Market Size by Application (2018-2023)
5.2 Global Tumor Immunity Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Tumor Immunity Therapy Market Size (2018-2029)
6.2 North America Tumor Immunity Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Tumor Immunity Therapy Market Size by Country (2018-2023)
6.4 North America Tumor Immunity Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumor Immunity Therapy Market Size (2018-2029)
7.2 Europe Tumor Immunity Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Tumor Immunity Therapy Market Size by Country (2018-2023)
7.4 Europe Tumor Immunity Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tumor Immunity Therapy Market Size (2018-2029)
8.2 Asia-Pacific Tumor Immunity Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Tumor Immunity Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Tumor Immunity Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tumor Immunity Therapy Market Size (2018-2029)
9.2 Latin America Tumor Immunity Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Tumor Immunity Therapy Market Size by Country (2018-2023)
9.4 Latin America Tumor Immunity Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor Immunity Therapy Market Size (2018-2029)
10.2 Middle East & Africa Tumor Immunity Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Tumor Immunity Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Tumor Immunity Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Introduction
11.1.4 Bristol-Myers Squibb Revenue in Tumor Immunity Therapy Business (2018-2023)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Merck & Co., Inc.
11.2.1 Merck & Co., Inc. Company Detail
11.2.2 Merck & Co., Inc. Business Overview
11.2.3 Merck & Co., Inc. Tumor Immunity Therapy Introduction
11.2.4 Merck & Co., Inc. Revenue in Tumor Immunity Therapy Business (2018-2023)
11.2.5 Merck & Co., Inc. Recent Development
11.3 Roche AG
11.3.1 Roche AG Company Detail
11.3.2 Roche AG Business Overview
11.3.3 Roche AG Tumor Immunity Therapy Introduction
11.3.4 Roche AG Revenue in Tumor Immunity Therapy Business (2018-2023)
11.3.5 Roche AG Recent Development
11.4 AstraZeneca, Plc
11.4.1 AstraZeneca, Plc Company Detail
11.4.2 AstraZeneca, Plc Business Overview
11.4.3 AstraZeneca, Plc Tumor Immunity Therapy Introduction
11.4.4 AstraZeneca, Plc Revenue in Tumor Immunity Therapy Business (2018-2023)
11.4.5 AstraZeneca, Plc Recent Development
11.5 Sanofi S.A.
11.5.1 Sanofi S.A. Company Detail
11.5.2 Sanofi S.A. Business Overview
11.5.3 Sanofi S.A. Tumor Immunity Therapy Introduction
11.5.4 Sanofi S.A. Revenue in Tumor Immunity Therapy Business (2018-2023)
11.5.5 Sanofi S.A. Recent Development
11.6 Dendreon Pharmaceuticals
11.6.1 Dendreon Pharmaceuticals Company Detail
11.6.2 Dendreon Pharmaceuticals Business Overview
11.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Introduction
11.6.4 Dendreon Pharmaceuticals Revenue in Tumor Immunity Therapy Business (2018-2023)
11.6.5 Dendreon Pharmaceuticals Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Tumor Immunity Therapy Introduction
11.7.4 Novartis Revenue in Tumor Immunity Therapy Business (2018-2023)
11.7.5 Novartis Recent Development
11.8 Gilead Sciences Inc.
11.8.1 Gilead Sciences Inc. Company Detail
11.8.2 Gilead Sciences Inc. Business Overview
11.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Introduction
11.8.4 Gilead Sciences Inc. Revenue in Tumor Immunity Therapy Business (2018-2023)
11.8.5 Gilead Sciences Inc. Recent Development
11.9 IMVAQ Therapeutics
11.9.1 IMVAQ Therapeutics Company Detail
11.9.2 IMVAQ Therapeutics Business Overview
11.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Introduction
11.9.4 IMVAQ Therapeutics Revenue in Tumor Immunity Therapy Business (2018-2023)
11.9.5 IMVAQ Therapeutics Recent Development
11.10 Arch Oncology
11.10.1 Arch Oncology Company Detail
11.10.2 Arch Oncology Business Overview
11.10.3 Arch Oncology Tumor Immunity Therapy Introduction
11.10.4 Arch Oncology Revenue in Tumor Immunity Therapy Business (2018-2023)
11.10.5 Arch Oncology Recent Development
11.11 Juno Therapeutics
11.11.1 Juno Therapeutics Company Detail
11.11.2 Juno Therapeutics Business Overview
11.11.3 Juno Therapeutics Tumor Immunity Therapy Introduction
11.11.4 Juno Therapeutics Revenue in Tumor Immunity Therapy Business (2018-2023)
11.11.5 Juno Therapeutics Recent Development
11.12 Refuge
11.12.1 Refuge Company Detail
11.12.2 Refuge Business Overview
11.12.3 Refuge Tumor Immunity Therapy Introduction
11.12.4 Refuge Revenue in Tumor Immunity Therapy Business (2018-2023)
11.12.5 Refuge Recent Development
11.13 Lepu Biopharma
11.13.1 Lepu Biopharma Company Detail
11.13.2 Lepu Biopharma Business Overview
11.13.3 Lepu Biopharma Tumor Immunity Therapy Introduction
11.13.4 Lepu Biopharma Revenue in Tumor Immunity Therapy Business (2018-2023)
11.13.5 Lepu Biopharma Recent Development
11.14 Genoimmune
11.14.1 Genoimmune Company Detail
11.14.2 Genoimmune Business Overview
11.14.3 Genoimmune Tumor Immunity Therapy Introduction
11.14.4 Genoimmune Revenue in Tumor Immunity Therapy Business (2018-2023)
11.14.5 Genoimmune Recent Development
11.15 TCR Cure
11.15.1 TCR Cure Company Detail
11.15.2 TCR Cure Business Overview
11.15.3 TCR Cure Tumor Immunity Therapy Introduction
11.15.4 TCR Cure Revenue in Tumor Immunity Therapy Business (2018-2023)
11.15.5 TCR Cure Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details